Isonest (Articaine Hydrochloride, Epinephrine Bitartrate)

Articaine hydrochloride blocks voltage‑gated sodium channels on nerve fibers, preventing the initiation and propagation of action potentials. This results in a reversible loss of sensation. The epinephrine component constricts local blood vessels, extending the anesthetic duration and limiting systemic exposure.

The appropriate dose of Isonest is determined by the prescribing clinician based on the specific procedure, patient age, weight and health status. Dosage guidelines are provided in the product’s prescribing information and must be individualized for each patient.

Safety data for Isonest in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and after careful consideration by the prescriber.

To request Isonest, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Isonest’s articaine component offers rapid onset and deep tissue penetration compared with lidocaine, while the epinephrine bitartrate prolongs its effect. It is often preferred for procedures requiring a fast, reliable block, but clinicians must consider patient‑specific factors and potential drug interactions.

Isonest should be stored at ambient temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight and extreme temperatures to maintain potency and sterility.

Isonest is supplied as a solution for injection and is administered by infiltration or perineural techniques. The clinician injects the solution directly into the target tissue or around the nerve to achieve localized anesthesia.

Serious risks include allergic reactions that may progress to anaphylaxis, seizures, cardiac arrhythmias or hypertension due to epinephrine, methemoglobinemia, and prolonged numbness or tissue necrosis at the injection site. Immediate medical attention is required if any of these occur.

Isonest should be avoided in patients with a known hypersensitivity to amide‑type local anesthetics or epinephrine, those taking non‑selective MAO inhibitors, and individuals with severe cardiac disease where epinephrine may exacerbate conditions. The prescriber must evaluate each patient’s medical history before use.